Literature DB >> 25638546

Anti-PD-L1 antibody active in metastatic bladder cancer.

Vicki Brower.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25638546     DOI： 10.1016/S1470-2045(14)71167-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  11 in total

Review 1.  Implications of Immunotherapy in Hepatobiliary Tumors.

Authors:  Aline Gottlieb; Jan Best; Ali Canbay
Journal:  Visc Med       Date:  2019-02-08

2.  Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.

Authors:  Zheng Wang; Chuanbao Zhang; Xing Liu; Zhiliang Wang; Lihua Sun; Guanzhang Li; Jingshan Liang; Huimin Hu; Yanwei Liu; Wei Zhang; Tao Jiang
Journal:  Oncoimmunology       Date:  2016-06-16       Impact factor: 8.110

3.  CRISPR-ON-Mediated KLF4 overexpression inhibits the proliferation, migration and invasion of urothelial bladder cancer in vitro and in vivo.

Authors:  Xin Xu; Jiangfeng Li; Yi Zhu; Bo Xie; Xiao Wang; Song Wang; Haiyun Xie; Huaqing Yan; Yufan Ying; Yiwei Lin; Ben Liu; Wei Wang; Xiangyi Zheng
Journal:  Oncotarget       Date:  2017-10-27

4.  Prognostic value of PD -L1 expression in patients with primary solid tumors.

Authors:  Xiao Xiang; Peng-Cheng Yu; Di Long; Xiao-Li Liao; Sen Zhang; Xue-Mei You; Jian-Hong Zhong; Le-Qun Li
Journal:  Oncotarget       Date:  2017-12-22

5.  Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy.

Authors:  Guan-Zhang Li; Ke-Nan Zhang; Zheng Wang; Hui-Min Hu; Zhi-Liang Wang; Ruo-Yu Huang; Hao-Yu Jiang; You Zhai; Yue-Mei Feng; Yuan-Hao Chang; Ren-Peng Li; Fan Wu; Fan Zeng; Tao Jiang; Wei Zhang
Journal:  Onco Targets Ther       Date:  2019-11-27       Impact factor: 4.147

6.  SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms.

Authors:  William D Hastings; Silvia Goldoni; Ye Wang; Morvarid Mohseni; Angelo Grauel; Javier Estrada Diez; Wei Guan; Simon Liang; Jiyoung Elizabeth Choi; Minying Pu; Dongshu Chen; Tyler Laszewski; Stephanie Schwartz; Jane Gu; Leandra Mansur; Tyler Burks; Lauren Brodeur; Roberto Velazquez; Steve Kovats; Bhavesh Pant; Giri Buruzula; Emily Deng; Julie T Chen; Farid Sari-Sarraf; Christina Dornelas; Malini Varadarajan; Haiyan Yu; Chen Liu; Joanne Lim; Huai-Xiang Hao; Xiaomo Jiang; Anthony Malamas; Matthew J LaMarche; Felipe Correa Geyer; Margaret McLaughlin; Carlotta Costa; Joel Wagner; David Ruddy; Pushpa Jayaraman; Nathaniel D Kirkpatrick; Pu Zhang; Oleg Iartchouk; Kimberly Aardalen; Viviana Cremasco; Glenn Dranoff; Jeffrey A Engelman; Serena Silver; Hongyun Wang
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

7.  Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, successfully treated by radical cystectomy with adjuvant chemotherapy: a case report.

Authors:  Mari Ohtaka; Takashi Kawahara; Yohei Kumano; Yoko Maeda; Takuya Kondo; Taku Mochizuki; Hiroaki Ishida; Yusuke Hattori; Jun-ichi Teranishi; Yasuhide Miyoshi; Yasushi Yumura; Masahiro Yao; Yoshiaki Inayama; Hiroji Uemura
Journal:  J Med Case Rep       Date:  2016-03-08

8.  The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.

Authors:  Ziying Lin; Yutong Xu; Yaxiong Zhang; Qihua He; Jianrong Zhang; Jianxing He; Wenhua Liang
Journal:  Oncotarget       Date:  2016-03-22

9.  Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.

Authors:  Takeshi Ieda; Satoru Muto; Fumitaka Shimizu; Masataka Taguri; Shigeto Yanada; Kousuke Kitamura; Kazutaka Terai; Keisuke Saito; Tatsuya Ogishima; Masayoshi Nagata; Hisamitsu Ide; Takatsugu Okegawa; Yoshiaki Wakumoto; Yoshiro Sakamoto; Akira Tsujimura; Raizo Yamaguchi; Kikuo Nutahara; Shigeo Horie
Journal:  EBioMedicine       Date:  2016-09-02       Impact factor: 8.143

10.  Combined inhibition of JAK1,2/Stat3‑PD‑L1 signaling pathway suppresses the immune escape of castration‑resistant prostate cancer to NK cells in hypoxia.

Authors:  Li-Jun Xu; Qi Ma; Jin Zhu; Jian Li; Bo-Xin Xue; Jie Gao; Chuan-Yang Sun; Ya-Chen Zang; Yi-Bin Zhou; Dong-Rong Yang; Yu-Xi Shan
Journal:  Mol Med Rep       Date:  2018-04-20       Impact factor: 2.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.